The annual report performance of 8 pharmaceutical companies is good!

On January 22, the annual report forecasts of listed companies in the pharmaceutical and biological industry continued to be disclosed, and they were basically pre-happy
.
The pre-happy pharmaceutical companies include Kangtuo Medical, Miracle Pharmaceutical, Luoxin Pharmaceutical, Lisheng Pharmaceutical, Rhine Biotechnology, etc.
Among them, Lisheng Pharmaceutical’s net profit increased by more than 1000%
.
Kangtuo Medical released the 2021 annual report performance forecast: It is expected to achieve a net profit of 76 million to 84 million yuan from January 1, 2021 to December 31, 2021, an increase of 45.
09% to 60.
36%, and a net profit of 5238.
14 in the same period last year.
million
.
For the reasons for the changes in performance, the company stated that it was mainly due to the increase in operating income
.
Miracle Pharma's 2021 annual report performance forecast shows that it is expected to achieve a net profit of 60 million to 72 million yuan in 2021, a net profit of -341.
2026 million yuan in the same period last year, and a basic earnings per share of -0.
64 yuan
.
The report shows that during the reporting period, the sales of the company's related products gradually recovered; at the same time, the company actively optimized the marketing organization structure and promoted the sales of major products
.
The 2021 annual report performance forecast disclosed by Hualan shares shows that it is expected to achieve a net profit of 200 million to 240 million yuan in 2021, an increase of 145.
83% to 194.
99%, and a net profit of 81.
3581 million yuan in the same period last year
.
The change in performance was mainly driven by a large number of vaccinations, and the sales of the company's vaccine rubber plugs increased significantly
.
Kanglong Chemical's 2021 annual report performance forecast shows that it is expected to achieve a net profit of 1.
582 billion yuan to 1.
699 billion yuan in 2021, an increase of 35% to 45%, and basic earnings per share of 1.
9925 yuan to 2.
1401 yuan
.
In the previous year, the company's net profit was 1.
172 billion yuan, and the basic earnings per share was 1.
4825 yuan
.
The company stated that during the reporting period, the company's business plan was carried out in an orderly manner, the main business income in 2021 will grow steadily, the scale efficiency and operational efficiency of mature service lines will gradually improve, and profitability will increase.

.
Luoxin Pharmaceutical expects to achieve a net profit of 450 million to 580 million yuan in 2021, an increase of 39.
61% to 79.
94%, and a basic earnings per share of 0.
31 to 0.
40 yuan
.
The net profit for the same period last year was 322.
3271 million yuan, and the basic earnings per share was 0.
22 yuan
.
The company said that with the weakening of the impact of the epidemic, the volume of outpatient visits and surgeries at medical terminals at all levels has gradually recovered
.
The sales volume of the company's products in the fields of digestion, respiration and antibiotics has rebounded
.
Lisheng Pharmaceutical's performance in 2021 is expected to increase significantly, with a net profit of 110 million to 140 million yuan, an increase of 1176.
80% to 1525.
02%, and a basic earnings per share of 0.
60 to 0.
77 yuan
.
The net profit for the same period last year was 8.
6153 million yuan, and the basic earnings per share was 0.
05 yuan
.
The company stated that in the face of the impact of the epidemic and industry changes, the company actively took effective measures to strengthen budget management and cost control, and compressed various controllable expenses.
In 2021, both sales and management expenses dropped significantly
.
Affected by the centralized maturity and interest settlement of the company's time deposits, the interest income of funds in 2021 increased compared with the previous year
.
Rhine Biotech expects to achieve a net profit of 112 million to 129 million yuan in 2021, an increase of 30.
25% to 50.
02%, and a basic earnings per share of 0.
20 to 0.
23 yuan
.
The net profit for the same period last year was 85.
9894 million yuan, and the basic earnings per share was 0.
15 yuan
.
The report shows that in the context of consumption upgrades in recent years, the plant extraction industry in which the company operates has ushered in good development opportunities
.
During the reporting period, the revenue of the company's plant extraction business continued to maintain a high growth trend, and it is expected that the year-on-year growth will reach more than 50%, which has fully compensated for the impact of the sharp decline in BT project revenue
.
Among them, the company's natural sugar-free sweetener business has a strong development momentum, and its revenue is expected to increase by more than 50% year-on-year
.
At the same time, the annual operating income of Huagao Bio, a controlled subsidiary of the company obtained through mergers and acquisitions, was included in the calculation of the consolidated statement, which also contributed to the operating performance during the reporting period.

.
Jinling Pharmaceutical's 2021 annual report performance forecast: It is expected to achieve a net profit of 101 million to 130 million yuan in 2021, an increase of 55% to 100%, and a basic earnings per share of 0.
2004 yuan to 0.
2579 yuan
.
The net profit for the same period last year was 65.
1365 million yuan, and the basic earnings per share was 0.
1292 yuan
.